Krystal Biotech, a preclinical gene therapy biotech focused on dermatological diseases, announced terms for its IPO on Thursday.
The Pittsburgh, PA-based company plans to raise $30 million by offering 3.0 million shares at a price range of $9 to $11. Insiders intend to purchase $5 million worth of shares in the offering. At the midpoint of the proposed range, Krystal Biotech would command a market value of $88 million.
Krystal Biotech was founded in 2015 and plans to list on the Nasdaq under the symbol KRYS. Ladenburg Thalmann & Co. is the sole bookrunner on the deal. It is expected to price during the week of September 18, 2017.
The article Gene therapy developer Krystal Biotech sets terms for $30 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
